Dual-targeted Drug Design of HER2 and HSP90 by CoMFA Model and Pharmacophore Analysis

被引：0
|
作者：
Huang, Hung-Jin [1 ]
Bau, Da-Tian [1 ,2 ,3 ]
Tsai, Ming-Hsui [3 ]
Hsu, Yuan-Man [1 ]
Ho, Tin-Yun [2 ]
Chen, Chien-Yu [1 ]
Chang, Yea-Huey [1 ]
Tsai, Fuu-Jen [4 ,5 ,6 ]
Tsai, Chang-Hai [7 ]
Chen, Calvin Yu-Chian [1 ,2 ,3 ,4 ]
机构：
[1] China Med Univ, Dept Biol Sci & Technol, Lab Pharmacoinformat & Nanotechnol, Taichung 40402, Taiwan
[2] China Med Univ, Grad Inst Chinese Med Sci, Taichung 40402, Taiwan
[3] China Med Univ, Terry Fox Canc Res Lab, Taichung 40402, Taiwan
[4] Univ Asia, Dept Bioinformat, Taichung 41354, Taiwan
[5] China Med Univ Hosp, Dept Med Genet Pediatr & Med Res, Taichung 404029, Taiwan
[6] China Med Univ, Coll Chinese Med, Taichung 40402, Taiwan
[7] Univ Asia, Dept Healthcare Adm, Taichung 41354, Taiwan
来源：
PROCEEDINGS OF THE 2009 2ND INTERNATIONAL CONFERENCE ON BIOMEDICAL ENGINEERING AND INFORMATICS, VOLS 1-4 | 2009年
关键词：
HER2; HSP90; Dual target; CoMFA; TYROSINE KINASE; INHIBITORS; DERIVATIVES; BINDING; CANCER; ZD6474;
D O I：
暂无
中图分类号：
TP18 [人工智能理论];
学科分类号：
081104 ; 0812 ; 0835 ; 1405 ;
摘要：
Heat shock protein 90 (HSP90) and human epidermal growth factor receptor 2 protein (HER2) are involved in several signal pathways for cancer cell proliferation. We focused on these two hallmarkers to design the dual-targeted inhibitors for cancer therapy. The comparative molecular field analysis (CoMFA) and pharmacophore analysis were employed for generating the predictive models. According the leave-one out (LOO) cross-validation, the CoMFA models obtained the significant r2 values of 0.978 and 0.974 for HSP90 and HER2, respectively. The contour maps of both targets indicated that there were amount of similar bulky favors area. Besides, the cost difference of pharmacophore models was 48.539 for 70% correlation with the experiment. The queries at 3-N and 6-N position of purine-based compound had the similar distributions. This study provided important information for design the HER2 and HSP90 dual-targeted inhibitors
引用
收藏
页码：837 / +
页数：3
相关论文
共 50 条
  • [41] HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer
    R Schulz
    F Streller
    A H Scheel
    J Rüschoff
    M-C Reinert
    M Dobbelstein
    N D Marchenko
    U M Moll
    Cell Death & Disease, 2014, 5 : e980 - e980
  • [42] HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer
    Schulz, R.
    Streller, F.
    Scheel, A. H.
    Rueschoff, J.
    Reinert, M-C
    Dobbelstein, M.
    Marchenko, N. D.
    Moll, U. M.
    CELL DEATH & DISEASE, 2014, 5 : e980 - e980
  • [43] ImmunoPET with 89Zr-DFO-trastuzumab: Monitoring the pharmacodynamic effects on HER2/neu expression by Hsp90 inhibition in vivo
    Holland, Jason P.
    Caldas-Lopes, Eloisi
    Divilov, Vadim
    Longo, Valerie A.
    Taldone, Tony
    Zatorska, Danuta
    Chiosis, Gabriela
    Lewis, Jason S.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [44] Long-term treatment with arsenite activates HER1 and HER2 through upregulating EGF, TGFα, and HSP90 in a human uroepithelial cell line
    Jin, Peiyu
    Liu, Jieyu
    Zhou, Qing
    Li, Sihao
    Liu, Weijue
    Xi, Shuhua
    CELL BIOLOGY AND TOXICOLOGY, 2020, 36 (03) : 279 - 284
  • [45] Long-term treatment with arsenite activates HER1 and HER2 through upregulating EGF, TGFα, and HSP90 in a human uroepithelial cell line
    Peiyu Jin
    Jieyu Liu
    Qing Zhou
    Sihao Li
    Weijue Liu
    Shuhua Xi
    Cell Biology and Toxicology, 2020, 36 : 279 - 284
  • [46] Measuring the Pharmacodynamic Effects of a Novel Hsp90 Inhibitor on HER2/neu Expression in Mice Using 89Zr-DFO-Trastuzumab
    Holland, Jason P.
    Caldas-Lopes, Eloisi
    Divilov, Vadim
    Longo, Valerie A.
    Taldone, Tony
    Zatorska, Danuta
    Chiosis, Gabriela
    Lewis, Jason S.
    PLOS ONE, 2010, 5 (01):
  • [47] The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells
    Alexandra Canonici
    Zulfiqar Qadir
    Neil T. Conlon
    Denis M. Collins
    Neil A. O’Brien
    Naomi Walsh
    Alex J. Eustace
    Norma O’Donovan
    John Crown
    Investigational New Drugs, 2018, 36 : 581 - 589
  • [48] The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells
    Canonici, Alexandra
    Qadir, Zulfiqar
    Conlon, Neil T.
    Collins, Denis M.
    O'Brien, Neil A.
    Walsh, Naomi
    Eustace, Alex J.
    O'Donovan, Norma
    Crown, John
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (04) : 581 - 589
  • [49] Assessing the Impact of HER2 Status on the Antitumor Activity of an HSP90 Inhibitor in Human Tumor Xenograft Mice Using Pharmacokinetic-Pharmacodynamic Modeling
    Saitoh, Ryoichi
    Nagayasu, Miho
    Shibahara, Norihito
    Ono, Naomi
    Suda, Atsushi
    Kato, Motohiro
    Ishigai, Masaki
    DRUG METABOLISM AND PHARMACOKINETICS, 2014, 29 (02) : 185 - 191
  • [50] Leptin increases HER2 protein levels through a STAT3-mediated up-regulation of Hsp90 in breast cancer cells
    Giordano, Cinzia
    Vizza, Donatella
    Panza, Salvatore
    Barone, Ines
    Bonofiglio, Daniela
    Lanzino, Marilena
    Sisci, Diego
    De Amicis, Francesca
    Fuqua, Suzanne A. W.
    Catalano, Stefania
    Ando, Sebastiano
    MOLECULAR ONCOLOGY, 2013, 7 (03) : 379 - 391
12345